- Home
- Publications
- Publication Search
- Publication Details
Title
Fms-like tyrosine kinase 3 positive acute myeloid leukemia
Authors
Keywords
-
Journal
CURRENT OPINION IN ONCOLOGY
Volume 35, Issue 6, Pages 589-593
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2023-10-12
DOI
10.1097/cco.0000000000000993
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2023) Harry P Erba et al. LANCET
- Acute myeloid leukaemia
- (2023) Courtney D DiNardo et al. LANCET
- Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia
- (2022) Marina Konopleva et al. CLINICAL CANCER RESEARCH
- Phase 3 Trial of Gilteritinib Plus Azacitidine Vs Azacitidine for Newly Diagnosed FLT3mut+ AML Ineligible for Intensive Chemotherapy
- (2022) Eunice S. Wang et al. BLOOD
- Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel
- (2022) Hartmut Döhner et al. BLOOD
- International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data
- (2022) Daniel A. Arber et al. BLOOD
- Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
- (2022) Naval Daver et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial
- (2022) Nikolaus Jahn et al. LEUKEMIA
- Long-Term Follow-up of the Phase 3 Viale-a Clinical Trial of Venetoclax Plus Azacitidine for Patients with Untreated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy
- (2022) Keith W. Pratz et al. BLOOD
- Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3-Internal Tandem Duplication: Results from the Quantum-First Trial
- (2022) Richard F. Schlenk et al. BLOOD
- Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia
- (2022) Nicholas Short et al. BLOOD
- High Deliverability of a Midostaurin Triplet Regimen Incorporating Venetoclax and Low Dose Cytarabine in Non-Adverse Cytogenetic Risk Acute Myeloid Leukaemia: A Sub-Analysis of the Australasian Leukaemia Lymphoma Group (ALLG) Intervene Study
- (2022) Chong Chyn Chua et al. BLOOD
- ELN Risk Stratification Is Not Predictive of Outcomes for Treatment-Naïve Patients with Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine
- (2022) Hartmut Döhner et al. BLOOD
- Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
- (2021) Abhishek Maiti et al. Blood Cancer Journal
- Acute myeloid leukemia: current progress and future directions
- (2021) Hagop Kantarjian et al. Blood Cancer Journal
- The changing landscape for patients with relapsed/refractory acute myeloid leukaemia
- (2021) Alessandro Isidori et al. CURRENT OPINION IN ONCOLOGY
- 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
- (2021) Michael Heuser et al. BLOOD
- Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN)
- (2020) Andreas Burchert et al. JOURNAL OF CLINICAL ONCOLOGY
- Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia
- (2020) Richard T. Maziarz et al. BONE MARROW TRANSPLANTATION
- FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies
- (2020) Vanessa E. Kennedy et al. Frontiers in Oncology
- Targeting FLT3 mutations in AML: review of current knowledge and evidence
- (2019) Naval Daver et al. LEUKEMIA
- Sorafenib Combined with 5-azacytidine (AZA) in Older Patients with Untreated FLT3 -ITD Mutated Acute Myeloid Leukemia (AML)
- (2018) Maro Ohanian et al. AMERICAN JOURNAL OF HEMATOLOGY
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome
- (2015) Paolo Strati et al. AMERICAN JOURNAL OF HEMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More